Business

Bayer MRI contrast agent gadoquatrane meets goals in phase 3 trials

Posted by

[ad_1]

Radiologist analyzing MRI scans on multiple computer monitors

alexey_ds/E+ via Getty Images

  • Bayer (OTCPK:BAYRY) said that phase 3 data on its experimental MRI contrast agent gadoquatrane met primary and secondary endpoints in phase 3 trials.
  • The QUANTI studies examined gadoquatrane at a gadolinium dose of 0.04 mmol Gd/kg body weight, a gadolinium dose

[ad_2]

Leave a Reply

Your email address will not be published. Required fields are marked *